"Moximed Raises $61M for Knee Osteoarthritis Treatment and Expands U.S. Commercialization Efforts"

Moximed raises $61M in Series D Financing

Moximed (Linkedin), a leader in knee osteoarthritis treatment, has secured $61M in Series D financing to accelerate the commercialization of their innovative MISHA® Knee System. This non-invasive solution provides relief for patients suffering from knee osteoarthritis, while reducing costs for insurance companies.

Funding Amount: $61 million (with an option for an additional $30 million)

Industry: Medical Equipment Manufacturing

Employee Count: 11-50

CEO: Christopher Gleason (CEO Linkedin)

What Moximed needs to buy: Moximed is seeking partnerships with marketing agencies, research institutions, and manufacturers to support the commercialization, validation, and production of their MISHA Knee System. Sales reps specializing in medical equipment, orthopedics, and insurance solutions should consider reaching out to Moximed for potential collaboration opportunities.